Norvasc Patent Still Invalid: Court

Law360, New York (May 21, 2007, 12:00 AM EDT) -- An appeals court refused Monday to rehear Pfizer Inc.’s case against Apotex Inc., giving the Canadian generics-maker the green light to launch a generic form of Pfizer’s blockbuster blood-pressure drug Norvasc.

The U.S. Court of Appeals for the Federal Circuit denied Pfizer’s request for an en banc rehearing and left intact its previous ruling that found the pharmaceutical behemoth’s patent for Norvasc unenforceable. In so doing, the court granted Apotex’ request that it expedite its issuance of the decision.

The court’s previous ruling, handed down March...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.